Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Advanced Treatment Approaches for Hidradenitis Suppurativa
Description
The discussion focuses on advanced treatment strategies for Hidradenitis Suppurativa (HS), a skin condition affecting approximately 1-4% of the population, particularly impacting quality of life and mental health. The presentation begins with an overview of HS, including its clinical phenotypes, racial disparities in prevalence and access to care, and advancements in understanding its pathophysiology. Treatment approaches are categorized into mild to severe disease, detailing various medical therapies such as antimicrobials, anti-TNF agents like adalimumab and infliximab, IL-17 inhibitors like secukinumab and bimikizumab, and JAK inhibitors like upadacitinib and tofacitinib. The significance of tailoring therapy to individual patient presentations and responses is emphasized, alongside the importance of setting realistic expectations regarding treatment efficacy and potential side effects. Novel therapies, such as IL-12 and IL-23 inhibitors and other agents in development, are also briefly mentioned. The presenter highlights the need for shared decision-making in managing HS and the importance of continuous research to further improve treatment outcomes.
View moreConclusions
- Hidradenitis suppurativa (HS) is more prevalent than previously thought, with estimates ranging from 1% to 4%.
- Access to care and diagnosis of HS is significantly affected by racial disparities.
- Advancements in the understanding of HS pathophysiology are informing new treatment approaches.
- Clinical phenotypes of HS vary widely, impacting treatment response and outcome measures.
- Current treatment strategies for mild HS include hormonal therapies, oral antibiotics, and lifestyle modifications.
- Biologics such as adalimumab and secukinumab have shown efficacy in moderate to severe HS, achieving significant clinical responses in patients.
- JAK inhibitors and other novel therapies are emerging as potential treatment options for HS.
- Effective management of HS often requires a personalized approach and consideration of patient-specific factors, including disease severity and treatment history.
- Therapeutic drug monitoring may enhance the effectiveness of treatment regimens for HS, particularly with anti-TNF therapies.
- Jemec GB. NEJM 2012; 366:158-164
- Vlassiva N, et al. AAD 2012; P4822
- Pink AE, et al. JID 2011; 131:1568-1570
- Anthony et al. Cureus 2023; 15(6): e41190
- Krueger et al. BJD 2024; 2: 149-162
- Zouboulis et al. JEADV 2015; 29:619-644
- Gisondi et al. JEADV 2023
- Katugampola et al. BJD 2007; 156: 945-950
- Kimball AB et al. JEADV 2016; 30(6): 989-994
- Kimabll AB et al. NEJM 2016; 375(5): 422-34
- Zoubloulis et al. JAAD 2018; 80(1): 60-69
- Holcomb et al. Expert Opinion on Drug Safety 2021; 20(10): 1147-1161
- Shih et al. Dermatol Ther 2022; 35 (9): e15691
- Wang and Micheletti JAAD 2019; 82(2): 507-510
- Demase et al J Clin Med 2023; 12(13): 4382
- Jyssum et al. Rheumatology (Oxford) epub Sept 2023
- van Huizan et al. J Invest Dermatol epub Nov 2023
- Kimball AB et al. AAD 2023, late-breaking abstract
- Adams et al. Front Immunol 2020
- Blok et al. BJD 2016; 174(4): 839-46
- Jiang et al. BJD 2022; 187(3): 417-419
- Kimball et al. JEADV 2023; 37(10): 2098-2108
- Dundink et al. BJD 2023; 188:601-609
- Kimball et al. Dermatol Ther (Heidelb) 2023;13(5):1099-1111
- Kim et al. J Allergy Clin Immunol 2023; 152(3): 656-666
- Nosrati et al JAMA Dermatology 2024; pub online 2/14/24
- Alavi et al. SKIN The Journal of Cutaneous Medicine 2023; 7 (6), s286
- Kirby et al. JAAD 2023; 90(3): 521-529